• Date not available
• Admin
• News Article

Palatin announces direct-to-consumer telehealth partnership with UpScriptHealth for Vyleesi

Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that it has entered a strategic partnership with UpScriptHealth, a leading direct-to-consumer telemedicine company providing telemedicine services to pharmaceutical and medical technology companies.

Under terms of the agreement, UpScriptHealth will make Vyleesi available to the hundreds of thousands of patients in its proprietary Women’s Telehealth Platform. Vyleesi is the first and only as-needed treatment approved by the US Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

“We are excited to partner with UpScriptHealth, a pioneer in telehealth,” stated Carl Spana, Ph.D., president and chief executive officer of Palatin. “This partnership fortifies our existing telehealth programmes and provides a platform to create greater awareness of HSDD and access to Vyleesi through UpScriptHealth’s patient base of hundreds of thousands of women.”

“UpScriptHealth’s Women’s Telehealth Platform was launched in 2015 to provide women with a convenient way to consult healthcare providers and obtain therapies to improve the quality of their lives,” stated Peter Ax, founder and chief executive officer of UpScriptHealth. “The addition of Vyleesi furthers our female health strategy and provides our patient base with education surrounding HSDD as a significant and common condition, and importantly, access to a meaningful treatment option.”

Vyleesi is the first and only as-needed treatment approved by the FDA for premenopausal women with acquired, generalized HSDD.

Palatin is actively seeking Vyleesi collaborations for the United States and for territories outside the currently licensed territories of China and South Korea. Vyleesi is licensed to Fosun Pharma in China and Kwangdong Pharmaceuticals in South Korea.

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential.

UpScriptHealth is the leading comprehensive, direct-to-consumer telehealth and virtual prescribing platform that has been innovating the way customers receive care and obtain medications for more than two decades.